Publications by authors named "Rutuja V Atale"
Article Synopsis
- Many patients with a tough kind of breast cancer called triple-negative breast cancer still have leftover cancer after treatment, making it more likely they'll have problems later on.
- Researchers looked at DNA and RNA from these leftover tumors to see what makes them different and how they change during treatment.
- They found some surprising results, like changes in genes that could help develop better treatments, but they didn't find a clear link between these changes and whether the cancer comes back or not.
Triple negative breast cancer accounts for 15-20% of all breast cancer cases, but despite its lower incidence, contributes to a disproportionately higher rate of mortality. As there are currently no Food and Drug Administration-approved targeted agents for triple negative breast cancer, we embarked on a genomic-guided effort to identify novel targeted modalities. Analyses by our group and The Cancer Genome Atlas have identified activation of the PI3K-pathway in the majority of triple negative breast cancers.
View Article and Find Full Text PDF